Drug Profile
Research programme: oncology companion diagnostics - Thermo Fisher Scientific
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Thermo Fisher Scientific
- Developer GSK; Institute of Medical Genetics and Pathology at University Hospital Basel; Pfizer; Thermo Fisher Scientific
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Cancer(Diagnosis) in Switzerland
- 28 May 2021 No recent reports of development identified for research development in Cancer(Diagnosis) in USA
- 26 Mar 2020 Thermo Fisher Scientific entered into a research and development agreement with Janssen Biotech to co-develop a companion diagnostic (CDx) in cancer